Prognosis of patients with ABL-class positive B-ALL: need for an early identification and establishment of a controlled study aimed at investigating the benefits of addition of a TKI to chemotherapy

ABL-class fusion positive cases other than BCR-ABL1 treated (AIEOP-BFM ALL 2000 and 2009 protocols)

- 13 Tyrosine kinase inhibitor during treatment
  - 1/13 Relapse
- 33 No Tyrosine kinase inhibitor during treatment
  - 8/33 Relapse

5-year probability of event-free survival: 49.1±8.9%
5-year probability of overall survival: 69.6±7.8%
Cumulative incidence of relapse: 25.6±8.2%
Treatment-related mortality: 20.8±6.8%

TKI + chemotherapy

ABL-class positive B-ALL

Good responders

TKI + chemotherapy

Poor responders

? Immunotherapy +/- TKI

HSCT in first CR

Cario et al., Haematologica, 2020